Background Methotrexate (MTX) is the first line drug in rheumatoid arthritis (RA) patients. However MTX couldn't be treated in RA patients due to renal failure. Iguratimod is a newly-developed disease-modifying antirheumatic drug (DMARD) that was approved in Japan in 2012. Iguratimod is not related with renal metastasis, and it is used for RA patients with chronic renal failure.
Objectives To evaluate the efficacy and safety of Iguratimod in RA patients with chronic renal failure in a cohort study design.
Methods RA patient (2010 ACR/EULAR criteria) with chronic renal failure (estimate GFR<50) were eligible if they had active disease despite treatment. Consecutive 21 patients with moderate to severe active RA patients (DAS28>3.2) were received Iguratimod plus previous DMARDs. Disease activity and renal function were assessed at baseline and 52 weeks follow-up. We compared disease activity and renal function at baseline with 52 weeks.
Results 18 patients were completed this study. DAS 28 was significantly improved from baseline to 52 weeks (baseline: 5.33±1.44, 52 weeks: 3.45±1.65, p<0.05). There were no patients that eGFR were worsened due to Iguratimod (baseline 65.4±12.2, 52 weeks 64.5±13.4, p=0.76).
Conclusions Iguratimod was effective and safety in RA patients with chronic renal failure. Iguratimod could be used for RA patients with chronic renal failure.
Acknowledgements We thank Dr Hiroshi Komori, Hiroyuki Ohta, and Naohiko Matsumoto at department of internal medicine, Hiroshima Clinic for checking data.
Disclosure of Interest None declared